B. Johnson

1.1k total citations
22 papers, 595 citations indexed

About

B. Johnson is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, B. Johnson has authored 22 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 5 papers in Clinical Psychology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in B. Johnson's work include Schizophrenia research and treatment (18 papers), Bipolar Disorder and Treatment (9 papers) and Gastrointestinal motility and disorders (4 papers). B. Johnson is often cited by papers focused on Schizophrenia research and treatment (18 papers), Bipolar Disorder and Treatment (9 papers) and Gastrointestinal motility and disorders (4 papers). B. Johnson collaborates with scholars based in United States, Austria and Denmark. B. Johnson's co-authors include Raymond Sanchez, Robert D. McQuade, William H. Carson, John M. Kane, Pamela Perry, W. Wolfgang Fleischhacker, Ross A. Baker, Na Jin, Anna Eramo and Timothy Peters-Strickland and has published in prestigious journals such as The British Journal of Psychiatry, Journal of Affective Disorders and Journal of Endodontics.

In The Last Decade

B. Johnson

21 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Johnson United States 11 559 135 125 119 76 22 595
W. Chrzanowski Poland 7 413 0.7× 46 0.3× 110 0.9× 96 0.8× 126 1.7× 11 497
Ilse Augustyns United States 7 665 1.2× 164 1.2× 57 0.5× 192 1.6× 54 0.7× 7 738
Yanning Liu United States 5 358 0.6× 73 0.5× 88 0.7× 73 0.6× 56 0.7× 8 389
Corina Young United Kingdom 9 530 0.9× 33 0.2× 154 1.2× 102 0.9× 84 1.1× 11 630
W. Gaebel Germany 10 431 0.8× 47 0.3× 164 1.3× 178 1.5× 52 0.7× 33 542
R. Marcus Germany 9 334 0.6× 81 0.6× 40 0.3× 99 0.8× 52 0.7× 26 387
L. Hargarter Germany 12 453 0.8× 38 0.3× 147 1.2× 151 1.3× 52 0.7× 33 497
R.N. Marcus United States 5 396 0.7× 43 0.3× 48 0.4× 59 0.5× 71 0.9× 10 449
C.G.G. Link United Kingdom 8 500 0.9× 39 0.3× 80 0.6× 79 0.7× 143 1.9× 14 585
Shubhra Mace United Kingdom 9 277 0.5× 38 0.3× 55 0.4× 93 0.8× 125 1.6× 14 467

Countries citing papers authored by B. Johnson

Since Specialization
Citations

This map shows the geographic impact of B. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Johnson more than expected).

Fields of papers citing papers by B. Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Johnson. The network helps show where B. Johnson may publish in the future.

Co-authorship network of co-authors of B. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of B. Johnson. A scholar is included among the top collaborators of B. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Johnson. B. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2018). The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study. Journal of Affective Disorders. 241. 425–432. 15 indexed citations
3.
Calabrese, Joseph R., Na Jin, B. Johnson, et al.. (2018). Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. International Journal of Bipolar Disorders. 6(1). 14–14. 10 indexed citations
4.
Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2017). Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder. The Journal of Clinical Psychiatry. 78(3). 324–331. 72 indexed citations
5.
Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2017). Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. Journal of Affective Disorders. 227. 649–656. 21 indexed citations
6.
Peters-Strickland, Timothy, Cathy Zhao, Pamela Perry, et al.. (2016). Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectrums. 21(6). 460–465. 7 indexed citations
7.
Kane, John M., Raymond Sanchez, Ross A. Baker, et al.. (2015). Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical Schizophrenia & Related Psychoses. 9(2). 79–87. 15 indexed citations
8.
Peters-Strickland, Timothy, Ross A. Baker, Robert D. McQuade, et al.. (2015). Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. Schizophrenia. 1(1). 15039–15039. 12 indexed citations
9.
Kane, John M., Cathy Zhao, B. Johnson, et al.. (2014). Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics. 18(2). 145–154. 41 indexed citations
10.
Fleischhacker, W. Wolfgang, Ross A. Baker, Anna Eramo, et al.. (2014). Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research. 159(2-3). 415–420. 21 indexed citations
11.
Fleischhacker, W. Wolfgang, Raymond Sanchez, Pamela Perry, et al.. (2014). Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. The British Journal of Psychiatry. 205(2). 135–144. 120 indexed citations
12.
Fleischhacker, W. Wolfgang, Pamela Perry, Raymond Sanchez, et al.. (2013). Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia. Value in Health. 16(7). A550–A550. 1 indexed citations
13.
Kane, John M., Raymond Sanchez, Joan Zhao, et al.. (2013). Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics. 16(7). 917–925. 41 indexed citations
14.
Fleischhacker, W. Wolfgang, Raymond Sanchez, B. Johnson, et al.. (2013). Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. International Clinical Psychopharmacology. 28(4). 1–1. 27 indexed citations
15.
Peters-Strickland, Timothy, W. Wolfgang Fleischhacker, Raymond Sanchez, et al.. (2013). P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole. European Neuropsychopharmacology. 23. S473–S474. 1 indexed citations
16.
Kane, John M., Raymond Sanchez, Pamela Perry, et al.. (2012). Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia. The Journal of Clinical Psychiatry. 73(5). 617–624. 167 indexed citations
17.
Sanchez, Raymond, Pamela Perry, Na Jin, et al.. (2012). P.3.c.018 A placebo-controlled study of efficacy/safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia. European Neuropsychopharmacology. 22. S327–S327. 3 indexed citations
18.
Nyilas, Margaretta, et al.. (2008). Long-term efficacy and safety of Aripiprazole in children (10-17 yo) with mania. European Psychiatry. 23. S232–S233. 8 indexed citations
19.
Forbes, Andrew, et al.. (2008). P.7.a.005 Long-term efficacy and safety of aripiprazole in children and adolescents with mania. European Neuropsychopharmacology. 18. S556–S557. 1 indexed citations
20.
Kolarevic, Branko, et al.. (1998). An Experiment in Design Collaboration. ACADIA quarterly. 90–99. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Chrzanowski Breakdown of academic impact, for papers by Ilse Augustyns Breakdown of academic impact, for papers by Yanning Liu Breakdown of academic impact, for papers by Corina Young Breakdown of academic impact, for papers by W. Gaebel Breakdown of academic impact, for papers by R. Marcus Breakdown of academic impact, for papers by L. Hargarter Breakdown of academic impact, for papers by R.N. Marcus Breakdown of academic impact, for papers by C.G.G. Link Breakdown of academic impact, for papers by Shubhra Mace
Rankless by CCL
2026